An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours
Schöffski, P., Adkins, D., Blay, J.-Y., Gil, T., Elias, A.D., Rutkowski, P., Pennock, G.K., Youssoufian, H., Gelderblom, H., Willey, R., Grebennik, D.O.Volume:
49
Langue:
english
Journal:
European Journal of Cancer
DOI:
10.1016/j.ejca.2013.06.010
Date:
October, 2013
Fichier:
PDF, 1.31 MB
english, 2013
File converter
Plus de résultats de recherche
More benefits 
